Combining Synthetic and Stem Cell Biology
Mark Kotter discusses how software-inspired approach to synthetic biology facilitates the targeting and reprogramming of entire sets of stem cells into other human cell types. By combining synthetic and stem cell biology, Mark and his team at bit.bio are providing stable supplies of human cell types for research and drug discovery. Video Transcript: (soft music) […]
Prominent ophthalmologist will guide Turn Bio’s search for therapies to cure eye diseases
MOUNTAIN VIEW, Calif., Aug. 22, 2022 /PRNewswire/ — Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that Albert Wu, MD, PhD, will oversee its development of ophthalmic therapeutic products as an advisor to the company. A board-certified ophthalmologist and fellowship-trained specialist in oculoplastic and orbital surgery, […]
Can stem cells shape the future of medicine? | Esther Wolfs
At this very moment, research is being done on Charcot-Marie-Tooth disease type 1A. Esther is a leading researcher in this field and will tell you more about how cancer and other global diseases can be cured using this new technique. Esther uses stem cells in anticancer therapy and as a model to study Charcot-Marie-Tooth disease […]
Harnessing Stem Cells to Treat Disease
Thanks to advances in techniques for culturing and genetically modifying patient cells, scientists developed myriad stem cell-based treatments for human diseases. Therapeutic success rates for stem cell-based treatments depend on whether scientists can provide the proper structural and molecular cues to form the cell types lacking in patients. In addition, to support successful engraftment, researchers […]
Immunis Announces FDA Clearance and Clinical Site for Phase 1/2a Clinical Trial Investigating Immune-Mediated Muscle Atrophy
IRVINE, Calif., Aug. 9, 2022 /PRNewswire/ — Immunis Inc., a private biotechnology company developing a novel treatment for age and disease-related immune decline, today announced that the U.S. Food and Drug Administration has approved it’s Investigational New Drug application for a Phase 1/2a clinical trial investigating IMM01-STEM in participants with muscle atrophy: www.clinicaltrials.gov/ct2/show/NCT05211986 The open label […]
Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio
MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ — Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that co-founder Vittorio Sebastiano, PhD, will become its head of research. Sebastiano led development of the unique mRNA-based ERA™ (Epigenetic Reprogramming of Aging) platform Turn Bio uses to produce tailored […]
RoslinCT and Lykan Bioscience Combine to Create Leading Advanced Cell Therapy CDMO
EDINBURGH, UK AND HOPKINTON, MA, 4 August 2022 – RoslinCT, a cell and gene therapy Contract Development and Manufacturing Organisation (‘CDMO’) developing life-changing therapies in Edinburgh’s BioQuarter, and Lykan Bioscience (‘Lykan’), an innovative CDMO focused on cell-based therapies, today announce that they have entered into a business combination agreement to form a global leading innovative […]
Global Mesenchymal Stem Cells Market Intelligence Report 2022: Industry to reach $5.84 Billion by 2027
Dublin, Aug. 03, 2022 (GLOBE NEWSWIRE) — The “Mesenchymal Stem Cells Market Intelligence Report – Global Forecast to 2027” report has been added to ResearchAndMarkets.com’s offering. The Global Mesenchymal Stem Cells Market is projected to reach USD 5,847.88 million by 2027 from USD 2,731.51 million in 2021, at a CAGR 13.52% during the forecast period. […]
TransCode Therapeutics and MD Anderson Announce Strategic Alliance to Advance RNA Therapies for Oncology
BOSTON and HOUSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA oncology company, and The University of Texas MD Anderson Cancer Center (“MD Anderson”), today announced a strategic alliance to advance TransCode’s pipeline of RNA-targeted oncology therapeutic and diagnostic candidates. Through the alliance, TransCode and MD […]
BrainStorm to Announce Second Quarter Results and Provide a Corporate Update
NEW YORK, Aug. 1, 2022 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that it will hold a conference call to update shareholders on financial results for the second quarter, ended on June 30, 2022, and provide a corporate update, at 8:00 a.m. Eastern […]